Biopsy-Driven Exploration of mCRPC

Subjects with mCRPC who were receiving standard-of-care therapy or treatment in a clinical trial [including trials combining AR therapies with other agents, a trial of the PARP inhibitor olaparib (37 (link)), and a trial of the Aurora kinase A inhibitor alisertib in patients with neuroendocrine features (14 (link))] and who had disease amenable to biopsy under radiographic guidance were considered for inclusion at one of seven SU2C-PCF (Stand Up to Cancer/Prostate Cancer Foundation) International Prostate Cancer Dream Team consortium sites (Dana-Farber Cancer Institute, Karmanos Cancer Institute, Memorial Sloan Kettering Cancer Center, Royal Marsden, University of Michigan, University of Washington, and Weill Cornell Medicine) (5 (link)). All subjects included in this study provided written consent for research use of tumor tissue with institutional review board approvals or appropriate waivers (Office of Human Research Studies at the Dana-Farber Cancer Institute, Wayne State University Institutional Review Board, Memorial Sloan Kettering Cancer Center Institutional Review Board/Privacy Board, Royal Marsden Ethics Committee, University of Michigan Medical School Institutional Review Board, University of Washington Institutional Review Board, and Weill Cornell Medicine Institutional Review Board). Clinical data, including treatment history, duration of therapy, and survival, were collected using a web-based electronic data capture. All samples and clinical data were deidentified.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Abida W., Cyrta J., Heller G., Prandi D., Armenia J., Coleman I., Cieslik M., Benelli M., Robinson D., Van Allen E.M., Sboner A., Fedrizzi T., Mosquera J.M., Robinson B.D., De Sarkar N., Kunju L.P., Tomlins S., Wu Y.M., Nava Rodrigues D., Loda M., Gopalan A., Reuter V.E., Pritchard C.C., Mateo J., Bianchini D., Miranda S., Carreira S., Rescigno P., Filipenko J., Vinson J., Montgomery R.B., Beltran H., Heath E.I., Scher H.I., Kantoff P.W., Taplin M.E., Schultz N., deBono J.S., Demichelis F., Nelson P.S., Rubin M.A., Chinnaiyan A.M, & Sawyers C.L. (2019). Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 116(23), 11428-11436.

Publication 2019

Alisertib Aurora kinase a Biopsy Cancer Dream Ethics committee Human Institutional review board Medicine Neuroendocrine Olaparib Parp inhibitor Patients Prostate cancer Radiographic Tissue Tumor

Corresponding Organization :

Other organizations : Memorial Sloan Kettering Cancer Center, Cornell University, University of Bern, University of Trento, Fred Hutch Cancer Center, University of Washington, University of Michigan–Ann Arbor, Dana-Farber Cancer Institute, Broad Institute, Institute of Cancer Research, National Health Service, Cancer Clinic, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Howard Hughes Medical Institute

Top 5 similar protocols

Protocol cited in 11 other protocols

Variable analysis

independent variables

Standard-of-care therapy or treatment in a clinical trial [including trials combining AR therapies with other agents, a trial of the PARP inhibitor olaparib, and a trial of the Aurora kinase A inhibitor alisertib in patients with neuroendocrine features]

dependent variables

Disease amenable to biopsy under radiographic guidance

control variables

All subjects included in this study provided written consent for research use of tumor tissue with institutional review board approvals or appropriate waivers
Clinical data, including treatment history, duration of therapy, and survival, were collected using a web-based electronic data capture
All samples and clinical data were deidentified

controls

Positive control: Not specified
Negative control: Not specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!